Purpose: Ablative radiotherapy (RT) improves clinical outcomes in patients with unresectable intrahepatic cholangiocarcinoma (ICC). Applicability to “supermassive” ICC remains uncertain given smaller tumor diameters in previous studies. We hypothesize that supermassive ICCs are not mutationally or histopathologically different from nonsupermassive ICCs and so would respond favorably to ablative RT. Experimental Design: This is a retrospective study of patients with supermassive ICC treated at the University of Texas MD Anderson Cancer Center (MDACC) and the National Cancer Database (NCDB). Patients treated at MDACC with unresectable ICC, ≥10 cm in diameter, treated with ablative RT or chemotherapy alone were included. Among NCDB patients, patients treated with chemotherapy alone were included. We analyzed overall survival (OS), tumor-related liver failure (TRLF), and treatment toxicity. We further analyzed mutational status and histopathology in supermassive and nonsupermassive ICC tumors. Results: We identified 63 patients treated at MDACC. Patients treated with RT showed improved OS compared with patients treated with chemotherapy alone (median OS: 28.7 vs. 11.9 months; adjusted HR = 0.4; P = 0.02). Patients treated with chemotherapy alone had a higher rate of TRLF compared with those who received RT (47.1% vs. 12.1%; P = 0.01). The RT cohort had improved OS compared with a frequency-matched NCDB chemotherapy-only cohort of supermassive ICC (37.6 vs. 8.9 months, P < 0.001). No major differences in mutational status or histopathology were noted between supermassive and nonsupermassive ICC tumors. Conclusions: Patients with supermassive ICC did not show a distinct mutational or histopathologic profile compared with those with nonsupermassive ICC and had promising outcomes with manageable toxicity when treated with ablative RT.
Designing phase III oncology trials to demonstrate overall survival (OS) superiority may be challenging due to sample size, follow-up time, resources, and costs as compared to trials evaluating intermediate endpoints, which may or may not be reliable surrogates of OS. In this study, we investigate at scale the relative gains in OS achieved in modern phase III oncology trials using OS primary endpoints in OPTIMA, a prospectively registered, pre-specified meta-analysis leveraging a large assembly of reconstructed individual patient-level data (PROSPERO: CRD420251162778). After screening 1184 trials and excluding 937 without an OS primary endpoint, 159 trials enrolling 104 740 patients met the inclusion criteria. In the two-stage Cox model, randomization to the experimental arm was associated with improvement in OS (random effects HR, 0.87; 95% CI, 0.85–0.89; P < .0001). In the one-stage Cox model stratified by trial identity, OS was also longer with the experimental arm (HR, 0.88; 95% CI, 0.85–0.90; P < .0001). Taken together, the data from OPTIMA should encourage renewed enthusiasm among trialists, funders, regulatory agencies, and policymakers for prioritizing phase III oncology trials evaluating OS primary endpoints.
PURPOSE: Randomized clinical trials (RCTs) are crucial to the advancement of cancer treatment, yet clinical trial participation remains consistently low. Laboratory-based eligibility criteria can strongly influence patient enrollment; however, the prevalence and specificity of such criteria used in oncologic RCTs remain uncharacterized. To address this, we sought to characterize the prevalence, specificity, and trial-level factors associated with laboratory-based eligibility criteria. METHODS: We conducted a meta-epidemiologic study of published phase III oncology RCTs registered on ClinicalTrials.gov. We assessed eligibility criteria for laboratory-based parameters including whether specific values were included. Multivariable logistic regression was used to evaluate the association of trial-level factors with study outcomes. RESULTS: A total of 1,180 RCTs enrolling 889,541 patients were included. Among these, 63% (n = 740) included laboratory criteria. Of the 740, 47% (n = 351) used vague terminology without specified thresholds. Cooperative group trials were associated with higher odds of using laboratory eligibility criteria in general (adjusted odds ratios [aOR], 3.11 [95% CI, 2.17 to 4.44]; P < .0001) and higher odds of using specific rather than vague criteria (aOR, 8.47 [95% CI, 5.35 to 13.4]; P < .0001). CONCLUSION: Although laboratory eligibility criteria are ubiquitous in phase III oncology RCTs, such criteria are often unspecified, which may affect enrollment and trial interpretation. Eligibility criteria of clinical trials should be tailored to those deemed essential for the safety and efficacy of participants undergoing the specific trial interventions.